Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

EXAI

Exscientia Plc ADR

Last Close
May 17 • 04:00PM ET
5.20
Dollar change
+0.07
Percentage change
1.36 		%
Scroll to Statements
Index- P/E- EPS (ttm)-1.46 Insider Own5.80% Shs Outstand125.70M Perf Week12.80%
Market Cap653.64M Forward P/E- EPS next Y-1.42 Insider Trans0.00% Shs Float118.41M Perf Month19.27%
Income-181.30M PEG- EPS next Q-0.37 Inst Own19.46% Short Float3.71% Perf Quarter-24.86%
Sales25.02M P/S26.12 EPS this Y8.63% Inst Trans0.77% Short Ratio7.05 Perf Half Y-13.04%
Book/sh3.61 P/B1.44 EPS next Y-3.49% ROA-25.31% Short Interest4.39M Perf Year-8.29%
Cash/sh3.68 P/C1.41 EPS next 5Y- ROE-35.22% 52W Range3.86 - 9.12 Perf YTD-18.88%
Dividend Est.- P/FCF- EPS past 5Y-116.17% ROI-38.20% 52W High-42.98% Beta0.84
Dividend TTM- Quick Ratio6.22 Sales past 5Y43.42% Gross Margin-113.56% 52W Low34.72% ATR (14)0.34
Dividend Ex-Date- Current Ratio6.22 EPS Y/Y TTM-23.84% Oper. Margin-899.55% RSI (14)55.78 Volatility5.42% 7.17%
Employees483 Debt/Eq0.05 Sales Y/Y TTM-25.77% Profit Margin-724.70% Recom2.50 Target Price9.50
Option/ShortYes / Yes LT Debt/Eq0.05 EPS Q/Q-9.42% Payout- Rel Volume1.52 Prev Close5.13
Sales Surprise-81.47% EPS Surprise-21.99% Sales Q/Q-62.27% EarningsMay 21 BMO Avg Volume622.59K Price5.20
SMA2010.80% SMA500.83% SMA200-9.52% Trades Volume944,400 Change1.36%
Date Action Analyst Rating Change Price Target Change
Jan-05-24Downgrade BofA Securities Buy → Neutral $11 → $9
May-16-24 07:15AM
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
(InvestorPlace)
May-14-24 07:00AM
Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024
(Business Wire)
May-03-24 10:01AM
Exscientia plc Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights EXAI
(GlobeNewswire) -8.25%
Mar-21-24 11:53AM
EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q4 2023
(InvestorPlace) -10.50%
07:00AM
Exscientia Business and Financial Update for the Full Year 2023
(Business Wire)
07:00AM Loading…
Mar-14-24 07:00AM
Exscientia to Report Full Year 2023 Financial Results on March 21, 2024
(Business Wire)
Mar-04-24 03:49PM
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
(InvestorPlace) -7.82%
Feb-28-24 07:00AM
Exscientia to Present at Upcoming Investor Conferences in March
(Business Wire) -5.62%
Feb-13-24 01:13PM
Oxford drug company sacks chief executive over inappropriate relationships with staff
(The Telegraph) -22.84%
08:52AM
Exscientia fires CEO after probe over relationship with two employees
(Reuters)
08:42AM
Exscientia fires CEO Andrew Hopkins over 'inappropriate' relationships with 2 employees
(FierceBiotech.com)
Feb-07-24 07:00AM
Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients
(Business Wire)
Jan-25-24 01:06PM
The Cutting Edge: 3 Stocks to Buy for the Next Generation of Biotech Breakthroughs
(InvestorPlace)
Jan-24-24 05:36AM
The Cutting Edge: 3 Stocks to Buy for the Next Generation of Biotech Breakthroughs
(InvestorPlace)
Jan-02-24 08:09AM
M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024
(InvestorPlace)
07:00AM Loading…
07:00AM
Professor Andrew L. Hopkins appointed Commander of the Order of the British Empire (CBE)
(Business Wire)
Dec-30-23 12:00PM
Ozempic drugmaker to open AI research hub in Kings Cross
(The Telegraph)
Dec-21-23 09:55AM
Wall Street Analysts See a 67.76% Upside in Exscientia PLC Sponsored ADR (EXAI): Can the Stock Really Move This High?
(Zacks) +5.32%
07:00AM
Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme
(Business Wire)
Dec-07-23 08:15AM
Looking for the Next Big Thing? Add This AI Biotech to Your Watch List Right Now
(Motley Fool) -8.06%
Dec-05-23 07:00AM
Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza
(Business Wire)
Dec-01-23 09:55AM
Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 68.03%: Read This Before Placing a Bet
(Zacks)
Nov-21-23 07:00AM
Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference
(Business Wire) -7.56%
Nov-15-23 09:55AM
Wall Street Analysts Believe Exscientia PLC Sponsored ADR (EXAI) Could Rally 76.12%: Here's is How to Trade
(Zacks)
Nov-14-23 12:06AM
3 Cutting-Edge Biotech Stocks for the Bold Investor
(InvestorPlace) +7.58%
Nov-10-23 01:24AM
Q3 2023 Exscientia PLC Earnings Call
(Thomson Reuters StreetEvents)
Nov-09-23 07:00AM
Exscientia Business Update for Third Quarter 2023
(Business Wire)
Nov-08-23 09:44AM
Is a Surprise Coming for Exscientia (EXAI) This Earnings Season?
(Zacks)
Nov-02-23 05:40PM
12 Stocks that Could Skyrocket According to Investment Newsletters
(Insider Monkey)
07:00AM
Exscientia to Report Third Quarter 2023 Financial Results on November 9, 2023
(Business Wire)
12:00PM Loading…
Oct-31-23 12:00PM
Top 12 Medical AI Companies
(Insider Monkey) +5.88%
Oct-30-23 09:55AM
Does Exscientia PLC Sponsored ADR (EXAI) Have the Potential to Rally 104.18% as Wall Street Analysts Expect?
(Zacks)
Oct-17-23 07:00AM
Parker Moss to Join Exscientia as EVP, Corporate Development
(Business Wire) -9.06%
Oct-16-23 07:00AM
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023
(Business Wire)
Oct-13-23 09:55AM
Wall Street Analysts Predict a 99.07% Upside in Exscientia PLC Sponsored ADR (EXAI): Here's What You Should Know
(Zacks) +7.96%
Oct-12-23 03:47AM
Exscientia PLC Sponsored ADR (EXAI) Stock Jumps 13.5%: Will It Continue to Soar?
(Zacks)
Oct-03-23 10:06AM
AI drug hunter Exscientia chops down 'rapidly emerging pipeline' to focus on 2 main oncology programs
(FierceBiotech.com) +5.52%
08:00AM
Exscientia Details Pipeline Prioritisation Strategy
(Business Wire)
Sep-21-23 09:35AM
Down -33.28% in 4 Weeks, Here's Why Exscientia PLC Sponsored ADR (EXAI) Looks Ripe for a Turnaround
(Zacks) +7.95%
Sep-20-23 01:00AM
Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
(Business Wire) -10.47%
Sep-15-23 08:45AM
3 AI Drug Discovery Stocks to Watch
(Motley Fool)
Sep-07-23 07:30PM
3 Med Tech Stocks That the AI Boom Will Only Help
(InvestorPlace)
Aug-31-23 07:00AM
Exscientia to Present at Upcoming Investor Conferences in September
(Business Wire) -5.35%
Aug-23-23 07:42PM
Biotech Breakthroughs: 3 Companies on the Cusp of Major Discoveries
(InvestorPlace) +7.44%
Aug-12-23 08:03AM
Exscientia plc (NASDAQ:EXAI) Analysts Just Trimmed Their Revenue Forecasts By 25%
(Simply Wall St.)
Aug-11-23 01:53AM
Q2 2023 Exscientia PLC Earnings Call
(Thomson Reuters StreetEvents)
Aug-10-23 07:00AM
Exscientia Business Update for Second Quarter and First Half of 2023
(Business Wire) -6.74%
Aug-03-23 07:00AM
Exscientia to Report Second Quarter 2023 Financial Results on August 10, 2023
(Business Wire)
Jul-30-23 03:00PM
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes
(InvestorPlace)
Jul-26-23 04:24PM
Biotech Stocks Join AI-Fueled Rally
(The Wall Street Journal)
Jul-21-23 06:10AM
News Flash: Analysts Just Made A Meaningful Upgrade To Their Exscientia plc (NASDAQ:EXAI) Forecasts
(Simply Wall St.)
Jul-18-23 07:00AM
Exscientia Initiates Prospective Observational Study in Ovarian Cancer
(Business Wire)
Jul-14-23 11:53AM
3 Biotech Stocks Using AI to Change Healthcare Forever
(InvestorPlace) -5.41%
Jul-12-23 04:51PM
Why Shares of Exscientia Jumped on Wednesday
(Motley Fool) +11.96%
Jul-10-23 07:00AM
GT Apeiron Announces Enrollment of First Patient in Phase 1/2 ELUCIDATE Clinical Trial of CDK7 Inhibitor, GTAEXS617, in Advanced Solid Tumors
(GlobeNewswire) +6.97%
07:00AM
First Patient Enrolled in Phase 1/2 "ELUCIDATE" Trial Assessing GTAEXS617 in Advanced Solid Tumours
(Business Wire)
Jun-29-23 11:00AM
We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate
(Simply Wall St.) -8.50%
08:05AM
Exscientia Announces Expansion of its Technology Leadership Team
(Business Wire)
Jun-06-23 07:00AM
Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
(Business Wire) +7.93%
May-26-23 03:24PM
3 Pharma Stocks That Will Boom Thanks to AI
(InvestorPlace)
11:23AM
Why Shares of Exscientia Soared This Week
(Motley Fool)
May-24-23 10:48PM
Q1 2023 Exscientia PLC Earnings Call
(Thomson Reuters StreetEvents) +6.04%
06:28PM
Why Artificial Intelligence Stock Exscientia Leaped 6% Higher Today
(Motley Fool)
07:00AM
Exscientia Business Update for First Quarter 2023
(Business Wire)
May-22-23 07:00AM
Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe
(Business Wire) +27.32%
May-17-23 07:01PM
Professor Andrew L. Hopkins elected Fellow of the Academy of Medical Sciences
(Business Wire) +6.18%
07:00AM
Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023
(Business Wire)
May-15-23 09:05AM
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
(Business Wire) +6.31%
May-10-23 05:01AM
Professor Andrew L. Hopkins elected Fellow of the Royal Society
(Business Wire) +8.07%
May-03-23 07:00AM
Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors
(Business Wire)
Apr-21-23 10:03AM
Exscientia plc's (NASDAQ:EXAI) largest shareholders are retail investors with 52% ownership, institutions own 27%
(Simply Wall St.) -5.04%
Apr-19-23 09:00AM
Data Presented at AACR 2023 Highlights Exscientias Clinical and Preclinical Development
(Business Wire) +6.62%
Mar-25-23 08:27AM
Exscientia Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag
(Simply Wall St.)
Mar-24-23 12:58AM
Q4 2022 Exscientia PLC Earnings Call
(Thomson Reuters StreetEvents) -10.07%
Mar-23-23 07:00AM
Exscientia Business and Financial Update for the Full Year 2022
(Business Wire) +10.49%
Mar-16-23 07:00AM
Exscientia to Report Full Year 2022 Financial Results on March 23, 2023
(Business Wire) +5.30%
Mar-15-23 07:00AM
Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR
(Business Wire)
Mar-14-23 07:00AM
Exscientia Announces Expansion of its Precision Oncology Pipeline
(Business Wire)
Mar-10-23 08:38AM
Exscientia (NASDAQ:EXAI) shareholders have endured a 55% loss from investing in the stock a year ago
(Simply Wall St.)
Mar-07-23 07:00AM
Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform
(Business Wire)
Feb-22-23 08:00AM
Exscientia to Present at Upcoming Investor Conferences in March
(Business Wire)
Feb-02-23 08:00AM
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
(Business Wire) +9.85%
Jan-20-23 09:23AM
Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans
(Simply Wall St.)
Dec-06-22 07:00AM
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress
(Business Wire) -9.62%
Nov-28-22 07:00AM
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
(Business Wire)
Nov-15-22 09:45AM
Exscientia PLC Sponsored ADR (EXAI) Reports Q3 Loss, Lags Revenue Estimates
(Zacks) -5.40%
08:00AM
Exscientia Business and Financial Update for the Third Quarter 2022
(Business Wire)
Nov-14-22 07:00AM
Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments
(Business Wire)
Nov-11-22 06:33AM
Institutions own 27% of Exscientia plc (NASDAQ:EXAI) shares but individual investors control 57% of the company
(Simply Wall St.) +12.14%
Nov-08-22 11:02PM
Evotec falls as U.K. writedown, expansion costs drive 9-month loss
(Investing.com)
07:00AM
Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022
(Business Wire)
Nov-03-22 05:35PM
Oncternal Therapeutics (ONCT) Reports Q3 Loss, Misses Revenue Estimates
(Zacks)
07:00AM
Exscientia Expands Biologics Design Capability with Automated Laboratory
(Business Wire)
Nov-01-22 08:00AM
Exscientia to Present at Upcoming Investor Conferences in November
(Business Wire)
Oct-28-22 09:05AM
Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award
(Business Wire)
Oct-26-22 08:00AM
Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium
(Business Wire)
Oct-01-22 08:40AM
Investors in Exscientia (NASDAQ:EXAI) from a year ago are still down 70%, even after 12% gain this past week
(Simply Wall St.)
Sep-20-22 09:00AM
Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes
(Business Wire)
Sep-08-22 08:00AM
Exscientia Welcomes Caroline Rowland as Chief People Officer
(Business Wire)
Sep-07-22 08:00AM
Exscientia to Present at Upcoming Investor Conferences in September
(Business Wire)
Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.